Markets are around the same levels as early Feb. However VHT has been hammered for simple reasons.Failure to deliver anything really meaningful. The half year report will provide more clarity to the doubters or amplify the current decline.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%